Boehringer’s Obesity Drug Achieves 16.6% Weight Loss in Trial; Further Data Pending
Boehringer’s investigational obesity drug demonstrated a 16.6% weight loss in a clinical trial, outperforming many existing treatments. However, addit...
Boehringer’s investigational obesity drug demonstrated a 16.6% weight loss in a clinical trial, outperforming many existing treatments. However, addit...
Novartis CEO Vas Narasimhan warns that President Trump's most-favored-nation drug pricing policy could disrupt global drug access and delay new treatm...
NFL tight end Greg Olsen is partnering with Novartis to promote prostate cancer screenings, urging men to overcome stigma. The campaign highlights the...